Biotech Blueprint

Biotech Blueprint

Home
Notes
This Week in Biotech
Deep Dives
Consulting
Archive
About
uniQure Wins a Surprise FDA Path in Huntington's, Moderna's mRNA Flu Vote, and a Record IPO Run – This Week in Biotech #105
The FDA reverses course on two products it had previously blocked, Lilly closes its fifteenth deal of 2026, and Kardigan pops 38% on debut to extend the…
 • Katerina Roznik
AstraZeneca Crashes the Obesity Party, Takeda Topples Sotyktu, and a Record Biotech IPO – This Week in Biotech #104
Elecoglipron makes obesity a four-player race, zasocitinib beats Bristol Myers Squibb head-to-head, and Parabilis prices the biggest venture-backed…
 • Katerina Roznik
China's First ASCO Plenary, a Standing Ovation for Daraxonrasib, and Washington's Counter-Move – This Week in Biotech #103
Akeso's ivonescimab beats a PD-1 inhibitor head-to-head in lung cancer, Revolution Medicines doubles survival in pancreatic cancer, and a House bill…
 • Katerina Roznik
GSK Functionally Cures Hepatitis B, Lilly's $3.8B Vaccine Pivot, and Base Editing Holds for 18 Months – This Week in Biotech #102
A landmark antisense win in 254 million patients, Lilly's tenth deal of 2026 redraws its franchise map, and Verve's base editor holds for 18 months (May…
 • Katerina Roznik
28% Weight Loss: Lilly's Retatrutide Just Redefined the Obesity Market – This Week in Biotech #101
Plus the covert campaign that took out Makary, and a 65% lung cancer trial win that could reshape Keytruda's future (May 15-21, 2026).
 • Katerina Roznik

Deep Dives

View all
Moderna in 2026: What the Wins and Losses Are Telling Us
Our latest podcast on the pattern across Moderna's pipeline, and why INT is the test that matters.
 • Katerina Roznik and The Biotech Capital Compass
Inside NImmune’s Phase 3 Push in Ulcerative Colitis
Founder Josep Bassaganya-Riera on omilancor, a gut-restricted oral therapy, precision biomarkers in inflammatory bowel disease, and the TITAN-X AI…
 • Katerina Roznik
Inside Sensible Biotechnologies: Reinventing mRNA Manufacturing
How an Oxford-born, YC-backed startup is betting that cell-based production will define mRNA’s next decade.
 • Katerina Roznik
How mRNA Could Defeat Latent Viruses and Train Immunity Against Cancer
Moderna and BioNTech deploy AI-driven mRNA to target CMV, EBV, HSV, and personalized neoantigen cancer vaccines. These trials could redefine…
 • Katerina Roznik and The Biotech Capital Compass
The mRNA Revolution: Beyond COVID to Cancer, Flu & Herpes Vaccines
How Moderna and BioNTech are expanding from COVID into CMV, EBV, HSV, and next-gen flu, while scaling personalized cancer vaccines (part 1 of the mRNA…
 • Katerina Roznik and The Biotech Capital Compass
Sarepta, Elevidys, and the Future of AAV Gene Therapy
Part 2 of a mini-series on gene therapies, from the perspective of a scientist and an investor.
 • Katerina Roznik and The Biotech Capital Compass
CRISPR in 2025: Clinical Use, Regulatory Pressure, and Future Promise
Part 1 of a mini-series on gene therapies, from the perspective of a scientist and an investor.
 • Katerina Roznik
Organoids, AI, and the FDA’s Move Away from Animal Models
Inside the FDA’s push to replace lab animals with human tissues & algorithms — with scientist Dr. Patrick Creisher.
 • Katerina Roznik
Podcasts
Apple Podcasts
Spotify
YouTube
Social Media
X
LinkedIn
Facebook
The latest from
Katerina Roznik
uniQure Wins a Surprise FDA Path in Huntington's, Moderna's mRNA Flu Vote, and a Record IPO Run – This Week in Biotech #105
User's avatar
Recommendations
Bio Breakdowns
Bio Breakdowns
Adu Subramanian
The Biotech Capital Compass
The Biotech Capital Compass
The Biotech Capital Compass
The Biotech Tea
The Biotech Tea
Annicka Evans, PhD

Recent posts

View all
Moderna in 2026: What the Wins and Losses Are Telling Us
Our latest podcast on the pattern across Moderna's pipeline, and why INT is the test that matters.
 • Katerina Roznik and The Biotech Capital Compass
Makary Resigns, BMS Bets $15B on China R&D, and Regenxbio Wins Phase 3 in Duchenne – This Week in Biotech #100
The FDA loses its commissioner amid mounting instability, BMS makes the biggest pharma-China deal of 2026, and a clean gene therapy dataset gives…
 • Katerina Roznik
FDA Approves the First PROTAC in History, a $1B siRNA Wave Hits Cardiometabolic Disease, and Cytokinetics Cracks Non-Obstructive HCM – This…
Targeted protein degradation gets its first regulatory template, Madrigal and GSK bet on genetically defined MASH and obesity, and aficamten wins where…
 • Katerina Roznik
The First In Vivo CRISPR Therapy to Win a Phase 3 Trial, and the $1.9B Acquisition Made Two Days Later – This Week in Biotech #98
Intellia's hereditary angioedema result validates in vivo gene editing, Sun Pharma makes the biggest biopharma deal of 2026, and the FDA draws a new…
 • Katerina Roznik
The Largest Biotech IPO on Record and a New HIV Treatment Option – This Week in Biotech #97
Merck's Idvynso offers the first integrase-free HIV switch option, Replimune cuts 60% of staff after a second FDA rejection, and Kailera's $625M debut…
 • Katerina Roznik
Biotech Blueprint
Biotech Blueprint
Biotech & pharma news, stocks, science, startups
Top posts
© 2026 Katerina · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for great culture